Crew Capital Management Ltd Invests $974,000 in Bristol Myers Squibb Company $BMY

Crew Capital Management Ltd purchased a new position in Bristol Myers Squibb Company (NYSE:BMY) during the 2nd quarter, HoldingsChannel.com reports. The fund purchased 16,907 shares of the biopharmaceutical company’s stock, valued at approximately $974,000.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. waypoint wealth counsel acquired a new position in Bristol Myers Squibb in the fourth quarter worth about $1,194,000. Life Cycle Investment Partners Ltd acquired a new stake in Bristol Myers Squibb during the fourth quarter valued at approximately $34,406,000. Lazard Asset Management LLC raised its stake in Bristol Myers Squibb by 23.7% during the first quarter. Lazard Asset Management LLC now owns 1,924,036 shares of the biopharmaceutical company’s stock valued at $116,693,000 after buying an additional 368,193 shares in the last quarter. Axxcess Wealth Management LLC lifted its holdings in Bristol Myers Squibb by 27.4% during the 4th quarter. Axxcess Wealth Management LLC now owns 98,665 shares of the biopharmaceutical company’s stock worth $5,322,000 after buying an additional 21,196 shares during the last quarter. Finally, Asset One Wealth Management LLC bought a new position in Bristol Myers Squibb during the 4th quarter worth approximately $4,075,000. Hedge funds and other institutional investors own 76.41% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages have recently weighed in on BMY. Jefferies Financial Group downgraded Bristol Myers Squibb from a “buy” rating to a “hold” rating in a report on Wednesday, August 5th. Sanford C. Bernstein upgraded Bristol Myers Squibb from a “market perform” rating to an “outperform” rating in a research note on Wednesday, August 5th. Truist Financial reaffirmed a “buy” rating and issued a $70.00 price objective (up from $65.00) on shares of Bristol Myers Squibb in a report on Friday, July 31st. Royal Bank Of Canada boosted their target price on shares of Bristol Myers Squibb from $60.00 to $64.00 and gave the company a “sector perform” rating in a research note on Friday, July 31st. Finally, Argus upgraded shares of Bristol Myers Squibb from a “hold” rating to a “buy” rating and set a $75.00 price target on the stock in a research report on Wednesday, August 5th. One equities research analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, eleven have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $66.06.

Bristol Myers Squibb News Summary

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: The U.S. FDA granted accelerated approval to ZENBEXUS, Bristol Myers Squibb’s first CELMoD therapy, in combination with daratumumab, hyaluronidase-fihj and dexamethasone for multiple myeloma patients as early as first relapse. The approval is strategically important because CELMoD drugs could help extend and rejuvenate the company’s important blood-cancer franchise. Bristol Myers wins milestone FDA approval of myeloma drug acquired from Celgene
• Positive Sentiment: Zacks Research raised its Bristol Myers Squibb EPS outlook for fiscal 2027 to $6.20 from $5.93. It also increased estimates for the fourth quarter of 2026, the first and second quarters of 2027, and the first two quarters of 2028, suggesting improved analyst expectations for earnings momentum.
• Positive Sentiment: The company expanded its kidney-disease pipeline with a Phase 1 study of golcadomide, providing another potential long-term growth opportunity beyond its established oncology products. Bristol-Myers Squibb expands kidney pipeline with new golcadomide renal study
• Neutral Sentiment: Rumors of a potential AstraZeneca-Bristol Myers Squibb merger have generated investor concern. Although a transaction could create a sizable oncology-focused pharmaceutical company, the strategic, financial and execution risks remain uncertain, and no deal was confirmed. Reported AstraZeneca-Bristol Myers Squibb megamerger
• Negative Sentiment: A federal appeals court revived a $6.7 billion lawsuit alleging Bristol Myers Squibb delayed approval of drugs acquired through Celgene, including Breyanzi. The case could create substantial financial liability and legal uncertainty. Lawsuit against Bristol Myers over delayed cancer drug is revived

Bristol Myers Squibb Stock Down 1.2%

Shares of Bristol Myers Squibb stock opened at $63.86 on Friday. The stock has a market capitalization of $130.45 billion, a price-to-earnings ratio of 14.07, a PEG ratio of 0.17 and a beta of 0.22. Bristol Myers Squibb Company has a twelve month low of $42.52 and a twelve month high of $68.10. The company has a current ratio of 1.53, a quick ratio of 1.38 and a debt-to-equity ratio of 1.89. The business’s 50 day simple moving average is $59.56 and its 200-day simple moving average is $58.97.

Bristol Myers Squibb (NYSE:BMY) last released its quarterly earnings data on Thursday, July 30th. The biopharmaceutical company reported $2.04 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.60 by $0.44. The business had revenue of $12.97 billion during the quarter, compared to analyst estimates of $11.74 billion. Bristol Myers Squibb had a return on equity of 66.90% and a net margin of 18.87%.The business’s revenue for the quarter was up 5.7% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $1.46 EPS. Bristol Myers Squibb has set its FY 2026 guidance at 6.750-7.000 EPS. Equities research analysts forecast that Bristol Myers Squibb Company will post 6.96 earnings per share for the current year.

Bristol Myers Squibb Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Monday, August 3rd. Stockholders of record on Thursday, July 2nd were issued a dividend of $0.63 per share. The ex-dividend date of this dividend was Thursday, July 2nd. This represents a $2.52 annualized dividend and a dividend yield of 3.9%. Bristol Myers Squibb’s payout ratio is 55.51%.

Bristol Myers Squibb Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late?stage pipeline reflect a strong emphasis on cancer and immune?mediated conditions.